Compare PD & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PD | RCKT |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | United States | United States |
| Employees | N/A | 202 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 636.9M | 534.2M |
| IPO Year | 2019 | N/A |
| Metric | PD | RCKT |
|---|---|---|
| Price | $6.18 | $3.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | $12.63 | ★ $29.65 |
| AVG Volume (30 Days) | 3.1M | ★ 3.9M |
| Earning Date | 03-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 416.95 | N/A |
| EPS | ★ 1.87 | N/A |
| Revenue | ★ $492,546,000.00 | N/A |
| Revenue This Year | $3.58 | N/A |
| Revenue Next Year | $1.65 | $51.17 |
| P/E Ratio | $3.21 | ★ N/A |
| Revenue Growth | ★ 5.36 | N/A |
| 52 Week Low | $5.92 | $2.19 |
| 52 Week High | $18.51 | $8.26 |
| Indicator | PD | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 30.75 | 40.19 |
| Support Level | $6.17 | $2.99 |
| Resistance Level | $16.47 | $4.08 |
| Average True Range (ATR) | 0.42 | 0.37 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 14.29 | 9.00 |
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.